{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:31:40Z","timestamp":1792636300991,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Idiopathic pulmonary fibrosis represents a lethal form of progressive fibrotic lung disorder with gradually increasing incidence worldwide. Despite intense research efforts its pathogenesis is still elusive and controversial reflecting in the current disappointing status regarding its treatment. Patients and Methods: We report the first protocol proposal of a prospective, unicentric, non-randomized, phase Ib clinical trial to study the safety and tolerability of the adipose-derived stem cells (ADSCs) stromal vascular fraction (SVF) as a therapeutic agent in IPF. After careful patient selection based on functional criteria (forced vital capacity-FVC &gt; 50%, diffuse lung capacity for carbon monoxide-DL<jats:sub>CO<\/jats:sub> &gt; 35% of the predicted values) all eligible subjects will be subjected to lipoaspiration resulting in the isolation of approximately 100- 500 gr of adipose tissue. After preparation, isolation and labelling ADSCs-SVF will be endobronchially infused to both lower lobes of the fibrotic lungs. Procedure will be repeated thrice at monthly intervals. Primary end-point represent safety and tolerability data, while exploratory secondary end-points include assessment of clinical functional and radiological status. Results: Preliminary results recently presented in the form of an abstract seem promising and tantalizing since there were no cases of clinically significant allergic reactions, infections, disease acute exacerbations or ectopic tissue formation. In addition 6 months follow-up data revealed a marginal improvement at 6-minute walking distance and forced vital capacity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Adipose tissue represents an abundant, safe, ethically uncontested and potentially beneficial source of stem cells for patients with IPF. Larger multicenter phase II and III placebo-controlled clinical trials are sorely needed in order to prove efficacy. However, pilot safety studies are of major importance and represent the first hamper that should be overcome to establish a rigid basis for larger clinical trials.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1479-5876-9-182","type":"journal-article","created":{"date-parts":[[2011,11,9]],"date-time":"2011-11-09T20:30:27Z","timestamp":1320870627000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Stem cell therapy for idiopathic pulmonary fibrosis: a protocol proposal"],"prefix":"10.1186","volume":"9","author":[{"given":"Argyris","family":"Tzouvelekis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Koliakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paschalis","family":"Ntolios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Baira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Bouros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Oikonomou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanassios","family":"Zissimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Kolios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despoina","family":"Kakagia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassilis","family":"Paspaliaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Kotsianidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marios","family":"Froudarakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demosthenes","family":"Bouros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,10,21]]},"reference":[{"key":"841_CR1","doi-asserted-by":"crossref","unstructured":"American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000, 161: 646-664.","DOI":"10.1164\/ajrccm.161.2.ats3-00"},{"key":"841_CR2","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK: An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011, 183: 788-824. 10.1164\/rccm.2009-040GL.","journal-title":"Am J Respir Crit Care Med"},{"key":"841_CR3","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.rmed.2009.03.001","volume":"103","author":"A Karakatsani","year":"2009","unstructured":"Karakatsani A, Papakosta D, Rapti A, Antoniou KM, Dimadi M, Markopoulou A: Epidemiology of interstitial lung diseases in Greece. Respir Med. 2009, 103: 1122-1129. 10.1016\/j.rmed.2009.03.001.","journal-title":"Respir Med"},{"key":"841_CR4","doi-asserted-by":"publisher","first-page":"e251","DOI":"10.1371\/journal.pmed.0020251","volume":"2","author":"A Pardo","year":"2005","unstructured":"Pardo A, Gibson K, Cisneros J, Richards TJ, Yang Y, Becerril C: Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med. 2005, 2: e251-10.1371\/journal.pmed.0020251.","journal-title":"PLoS Med"},{"key":"841_CR5","doi-asserted-by":"publisher","first-page":"136","DOI":"10.7326\/0003-4819-134-2-200101160-00015","volume":"134","author":"M Selman","year":"2001","unstructured":"Selman M, King TE, Pardo A: Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001, 134: 136-151.","journal-title":"Ann Intern Med"},{"key":"841_CR6","first-page":"165","volume":"21","author":"M Selman","year":"2004","unstructured":"Selman M, Pardo A: Idiopathic pulmonary fibrosis: misunderstandings between epithelial cells and fibroblasts?. Sarcoidosis Vasc Diffuse Lung Dis. 2004, 21: 165-172.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"841_CR7","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1164\/rccm.200504-644OC","volume":"173","author":"M Selman","year":"2006","unstructured":"Selman M, Pardo A, Barrera L, Estrada A, Watson SR, Wilson K: Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am J Respir Crit Care Med. 2006, 173: 188-198.","journal-title":"Am J Respir Crit Care Med"},{"key":"841_CR8","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1164\/rccm.200705-683OC","volume":"176","author":"A Tzouvelekis","year":"2007","unstructured":"Tzouvelekis A, Harokopos V, Paparountas T, Oikonomou N, Chatziioannou A, Vilaras G: Comparative expression profiling in pulmonary fibrosis suggests a role of hypoxia-inducible factor-1alpha in disease pathogenesis. Am J Respir Crit Care Med. 2007, 176: 1108-1119. 10.1164\/rccm.200705-683OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"841_CR9","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1172\/JCI200420997","volume":"114","author":"RJ Phillips","year":"2004","unstructured":"Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY: Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest. 2004, 114: 438-446.","journal-title":"J Clin Invest"},{"key":"841_CR10","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nri1412","volume":"4","author":"TA Wynn","year":"2004","unstructured":"Wynn TA: Fibrotic disease and the T(H)1\/T(H)2 paradigm. Nat Rev Immunol. 2004, 4: 583-594. 10.1038\/nri1412.","journal-title":"Nat Rev Immunol"},{"key":"841_CR11","doi-asserted-by":"crossref","unstructured":"The IPFnet Strategy: Creating a comprehensive approach in the treatment of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2010, 181: 527-528.","DOI":"10.1164\/rccm.200903-0483ED"},{"key":"841_CR12","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1183\/09031936.05.00145004","volume":"26","author":"D Bouros","year":"2005","unstructured":"Bouros D, Antoniou KM: Current and future therapeutic approaches in idiopathic pulmonary fibrosis. Eur Respir J. 2005, 26: 693-702. 10.1183\/09031936.05.00145004.","journal-title":"Eur Respir J"},{"key":"841_CR13","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","volume":"377","author":"PW Noble","year":"2011","unstructured":"Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D: Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011, 377: 1760-1769. 10.1016\/S0140-6736(11)60405-4.","journal-title":"Lancet"},{"key":"841_CR14","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1016\/S0140-6736(11)60546-1","volume":"377","author":"D Bouros","year":"2011","unstructured":"Bouros D: Pirfenidone for idiopathic pulmonary fibrosis. Lancet. 2011, 377: 1727-1729. 10.1016\/S0140-6736(11)60546-1.","journal-title":"Lancet"},{"key":"841_CR15","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1056\/NEJMoa042976","volume":"353","author":"M Demedts","year":"2005","unstructured":"Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM: High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005, 353: 2229-2242. 10.1056\/NEJMoa042976.","journal-title":"N Engl J Med"},{"key":"841_CR16","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1378\/chest.09-0848","volume":"136","author":"G Raghu","year":"2009","unstructured":"Raghu G: Improving the standard of care for patients with idiopathic pulmonary fibrosis requires participation in clinical trials. Chest. 2009, 136: 330-333. 10.1378\/chest.09-0848.","journal-title":"Chest"},{"key":"841_CR17","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1182\/blood-2004-07-2921","volume":"105","author":"S Beyth","year":"2005","unstructured":"Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H: Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood. 2005, 105: 2214-2219. 10.1182\/blood-2004-07-2921.","journal-title":"Blood"},{"key":"841_CR18","doi-asserted-by":"publisher","first-page":"13625","DOI":"10.1073\/pnas.240309797","volume":"97","author":"S Gronthos","year":"2000","unstructured":"Gronthos S, Mankani M, Brahim J, Robey PG, Shi S: Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. Proc Natl Acad Sci USA. 2000, 97: 13625-13630. 10.1073\/pnas.240309797.","journal-title":"Proc Natl Acad Sci USA"},{"key":"841_CR19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1532\/IJH97.06230","volume":"86","author":"B Hall","year":"2007","unstructured":"Hall B, Dembinski J, Sasser AK, Studeny M, Andreeff M, Marini F: Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles. Int J Hematol. 2007, 86: 8-16. 10.1532\/IJH97.06230.","journal-title":"Int J Hematol"},{"key":"841_CR20","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1016\/j.jacc.2009.06.055","volume":"54","author":"JM Hare","year":"2009","unstructured":"Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP: A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009, 54: 2277-2286. 10.1016\/j.jacc.2009.06.055.","journal-title":"J Am Coll Cardiol"},{"key":"841_CR21","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/MCP.0b013e328348744f","volume":"17","author":"A Tzouvelekis","year":"2011","unstructured":"Tzouvelekis A, Antoniadis A, Bouros D: Stem cell therapy in pulmonary fibrosis. Curr Opin Pulm Med. 2011, 17: 368-373. 10.1097\/MCP.0b013e328348744f.","journal-title":"Curr Opin Pulm Med"},{"key":"841_CR22","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1165\/rcmb.F315","volume":"34","author":"BR Stripp","year":"2006","unstructured":"Stripp BR, Shapiro SD: Stem cells in lung disease, repair, and the potential for therapeutic interventions: State-of-the-art and future challenges. Am J Respir Cell Mol Biol. 2006, 34: 517-518. 10.1165\/rcmb.F315.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"841_CR23","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/S0140-6736(08)60666-2","volume":"371","author":"D Wolf","year":"2008","unstructured":"Wolf D, Wolf AM: Mesenchymal stem cells as cellular immunosuppressants. Lancet. 2008, 371: 1553-1554. 10.1016\/S0140-6736(08)60666-2.","journal-title":"Lancet"},{"key":"841_CR24","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1164\/rccm.200706-859OC","volume":"177","author":"V Sueblinvong","year":"2008","unstructured":"Sueblinvong V, Loi R, Eisenhauer PL, Bernstein IM, Suratt BT, Spees JL: Derivation of lung epithelium from human cord blood-derived mesenchymal stem cells. Am J Respir Crit Care Med. 2008, 177: 701-711. 10.1164\/rccm.200706-859OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"841_CR25","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.4049\/jimmunol.179.3.1855","volume":"179","author":"N Gupta","year":"2007","unstructured":"Gupta N, Su X, Popov B, Lee JW, Serikov V, Matthay MA: Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol. 2007, 179: 1855-1863.","journal-title":"J Immunol"},{"key":"841_CR26","doi-asserted-by":"publisher","first-page":"8407","DOI":"10.1073\/pnas.1432929100","volume":"100","author":"LA Ortiz","year":"2003","unstructured":"Ortiz LA, Gambelli F, McBride C, Gaupp D, Baddoo M, Kaminski N: Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA. 2003, 100: 8407-8411. 10.1073\/pnas.1432929100.","journal-title":"Proc Natl Acad Sci USA"},{"key":"841_CR27","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1164\/rccm.201001-0126OC","volume":"183","author":"KS Schweitzer","year":"2011","unstructured":"Schweitzer KS, Johnstone BH, Garrison J, Rush NI, Cooper S, Traktuev DO: Adipose stem cell treatment in mice attenuates lung and systemic injury induced by cigarette smoking. Am J Respir Crit Care Med. 2011, 183: 215-225. 10.1164\/rccm.201001-0126OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"841_CR28","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1056\/NEJMoa1101324","volume":"364","author":"J Kajstura","year":"2011","unstructured":"Kajstura J, Rota M, Hall SR, Hosoda T, D'Amario D, Sanada F: Evidence for human lung stem cells. N Engl J Med. 2011, 364: 1795-1806. 10.1056\/NEJMoa1101324.","journal-title":"N Engl J Med"},{"key":"841_CR29","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1634\/stemcells.2005-0234","volume":"24","author":"JB Mitchell","year":"2006","unstructured":"Mitchell JB, McIntosh K, Zvonic S, Garrett S, Floyd ZE, Kloster A: Immunophenotype of human adipose-derived cells: temporal changes in stromal-associated and stem cell-associated markers. Stem Cells. 2006, 24: 376-385. 10.1634\/stemcells.2005-0234.","journal-title":"Stem Cells"},{"key":"841_CR30","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1479-5876-8-16","volume":"8","author":"F Lin","year":"2010","unstructured":"Lin F, Josephs SF, Alexandrescu DT, Ramos F, Bogin V, Gammill V: Lasers, stem cells, and COPD. J Transl Med. 2010, 8: 16-10.1186\/1479-5876-8-16.","journal-title":"J Transl Med"},{"key":"841_CR31","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1378\/chest.10-0518","volume":"138","author":"MA Matthay","year":"2010","unstructured":"Matthay MA, Thompson BT, Read EJ, McKenna DH, Liu KD, Calfee CS: Therapeutic potential of mesenchymal stem cells for severe acute lung injury. Chest. 2010, 138: 965-972. 10.1378\/chest.10-0518.","journal-title":"Chest"},{"key":"841_CR32","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/00000658-199801000-00013","volume":"227","author":"J Werner","year":"1998","unstructured":"Werner J, Dragotakes SC, Fernandez-del CC, Rivera JA, Ou J, Rattner DW: Technetium-99m-labeled white blood cells: a new method to define the local and systemic role of leukocytes in acute experimental pancreatitis. Ann Surg. 1998, 227: 86-94. 10.1097\/00000658-199801000-00013.","journal-title":"Ann Surg"},{"key":"841_CR33","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00441-007-0479-2","volume":"331","author":"DN Kotton","year":"2008","unstructured":"Kotton DN, Fine A: Lung stem cells. Cell Tissue Res. 2008, 331: 145-156. 10.1007\/s00441-007-0479-2.","journal-title":"Cell Tissue Res"},{"key":"841_CR34","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1513\/pats.200804-037DW","volume":"5","author":"DJ Weiss","year":"2008","unstructured":"Weiss DJ, Kolls JK, Ortiz LA, Panoskaltsis-Mortari A, Prockop DJ: Stem cells and cell therapies in lung biology and lung diseases. Proc Am Thorac Soc. 2008, 5: 637-667. 10.1513\/pats.200804-037DW.","journal-title":"Proc Am Thorac Soc"},{"key":"841_CR35","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1517\/14712598.3.5.705","volume":"3","author":"JM Gimble","year":"2003","unstructured":"Gimble JM: Adipose tissue-derived therapeutics. Expert Opin Biol Ther. 2003, 3: 705-713. 10.1517\/14712598.3.5.705.","journal-title":"Expert Opin Biol Ther"},{"key":"841_CR36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4252\/wjsc.v3.i4.25","volume":"3","author":"L Casteilla","year":"2011","unstructured":"Casteilla L, Planat-Benard V, Laharrague P, Cousin B: Adipose-derived stromal cells: Their identity and uses in clinical trials, an update. World J Stem Cells. 2011, 3: 25-33. 10.4252\/wjsc.v3.i4.25.","journal-title":"World J Stem Cells"},{"key":"841_CR37","first-page":"3s","volume":"176","author":"A Tzouvelekis","year":"2011","unstructured":"Tzouvelekis A, Paspaliaris V, Koliakos G, Ntolios P, Oikonomou A, Froudarakis M: A prospective, non randomized, clinical trial to study the safety and efficacy of the endobronchial autologous infusion of adipose-derived mesenchymal stem cells (ADMSCs) in patients with idiopathic pulmonary fibrosis (IPF). Eur Respir J. 2011, 176: 3s-","journal-title":"Eur Respir J"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1479-5876-9-182.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T17:05:45Z","timestamp":1630515945000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/1479-5876-9-182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,21]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["841"],"URL":"https:\/\/doi.org\/10.1186\/1479-5876-9-182","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,21]]},"assertion":[{"value":"15 August 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"182"}}